ACR Convergence 2021—The Great Debate at the meeting sparked a thoughtful discussion on the future of lupus nephritis treatment strategies, with experts saying clinicians should be open to new ways of approaching patient care. In the past year, approvals of the monoclonal antibody belimumab and the calcineurin inhibitor voclosporin for use in lupus nephritis (when…
Using the 2019 EULAR/ACR Classification Criteria to Predict Disease Severity in SLE
Predicting a patient’s disease course is difficult, especially in SLE. A recent study examined the link between a patient’s 2019 EULAR/ACR SLE Classification Criteria score at diagnosis to subsequent disease severity, finding a score of 20 or more may predict a more severe disease course.
How Pediatric Rheumatologists Are Moving Lupus Research Forward
In the 2021 Edmund L. Dubois, MD, Memorial Lectureship, Aimee Hersh, MD, discussed her work on defining research priorities in pediatric lupus.
Top 12: Research in Systemic Lupus Erythematosus at a Glance
Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.
Case Report: Is It Castleman Disease, or Castleman-Like?
The difference between Castleman disease and Castleman-like disease may be subtle, but it comes with significant ramifications. Case Presentation This case involves a pregnant 19-year-old woman who presents over multiple hospitalizations with concerns for systemic lupus erythematosus and macrophage activation syndrome. At 36 weeks’ gestation, the patient’s weight had dropped from 215 lbs. to 170…
Rituximab for Children with Lupus Nephritis
NEW YORK (Reuters Health)—Pediatric rheumatologists and nephrologists appear to differ in their treatment choices for children who have lupus nephritis (LN), with rheumatologists more likely to prescribe rituximab, results of a small survey suggest. “This study highlights the importance of collaborative effort in developing CTPs (Consensus Treatment Plans) for pediatric LN,” the authors write in…
Case Report: Drug-Induced Lupus
The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…
Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More
PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…
2-Year Extension Study Supports Voclosporin to Treat Patients with Lupus Nephritis
Research has shown voclosporin in combination with MMF and low-dose steroids benefits patients with lupus nephritis, significantly increasing the speed of remission. New data from an ongoing extension study demonstrate a positive risk/benefit profile.
2 Cases of SLE-Associated Diffuse Alveolar Hemorrhage
Pulmonary manifestations in patients with systemic lupus erythematosus (SLE) include pleuritis, acute pneumonitis, interstitial lung disease, pulmonary arterial hypertension, shrinking lung syndrome and diffuse alveolar hemorrhage (DAH). DAH is a rare, but devastating, complication of SLE, with high mortality rates. The incidence of DAH in SLE ranges from 0.6% to 5.4%, but the mortality rate…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 40
- Next Page »